[The RAS paradox of the EGFR-targeted therapy in colorectal cancer]

Related Experiment Video

Updated: Jul 3, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

József Tímár1, István Láng

  • 1Országos Onkológiai Intézet 1122 Budapest Ráth György u. 7-9. jtimar@oncol.hu

Magyar Onkologia
|July 22, 2008
PubMed

Insights

K-RAS mutations in colorectal cancer predict poor response to anti-EGFR therapies. Determining K-RAS status is crucial for selecting effective targeted treatments and improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) development involves early mutations in K-RAS (approx. 50% of cases) and less frequently B-RAF.
  • K-RAS and B-RAF mutations show distinct demographic associations (e.g., K-RAS in males, B-RAF in females).
  • Epidermal Growth Factor Receptor (EGFR) is characteristically expressed in CRC, but rarely mutated or amplified.

Purpose of the Study:

  • To evaluate the role of K-RAS mutation status as a predictive biomarker for anti-EGFR antibody therapies in colorectal cancer.
  • To determine if K-RAS status influences the efficacy of targeted therapies like panitumumab and cetuximab in CRC.

Main Methods:

  • Analysis of K-RAS and B-RAF mutation status in colorectal adenomas and tumors.
  • Review of clinical data on anti-EGFR antibody monotherapy and combination therapy response rates.
  • Correlation of tumor genotype (K-RAS status) with treatment outcomes in patients with colorectal cancer.

Main Results:

  • Anti-EGFR antibody monotherapies showed limited response rates (approx. 10%) irrespective of EGFR expression levels.
  • Tumor efficacy for panitumumab was found to be dependent on K-RAS wild-type status.
  • Preliminary data indicate cetuximab combined with chemotherapy is effective primarily in K-RAS wild-type colorectal cancer.

Conclusions:

  • K-RAS mutant status is a significant negative predictor for the efficacy of EGFR-targeted therapies in colorectal cancer.
  • Determining the K-RAS mutation status is essential for informed therapeutic decision-making in colorectal cancer patients.
  • This finding supports personalized medicine approaches in CRC treatment selection.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...